TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05765838

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (NPS right - Nasal swab left - OPS)
Description: Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (NPS left - Nasal swab right - OPS)
Description: Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (Nasal swab right - NPS left - OPS)
Description: Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (Nasal swab left - NPS right - OPS)
Description: Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (NPS right - OPS - Nasal swab left)
Description: Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (NPS left - OPS - Nasal swab right)
Description: Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (Nasal swab right - OPS - NPS left)
Description: Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (Nasal swab left - OPS - NPS right)
Description: Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (OPS - NPS right - Nasal swab left)
Description: Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (OPS - NPS left - Nasal swab right)
Description: Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (OPS - Nasal swab left - NPS right)
Description: Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: (OPS - Nasal swab right - NPS left)
Description: Collection of nasopharyngeal-, nasal-, and oropharyngeal swabs in randomized order
Study: NCT04685317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentinel® Cerebral Protection System
Description: A percutaneously delivered dual-filter protection device, designed to capture and remove debris dislodged during transcatheter aortic valve replacement procedures.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Cerebral MRI will be performed without gadolinium contrast using a 3 Tesla scanner prior to and 1 to 7 days after catheter ablation
Study: NCT06028399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concurrent Training
Description: The patient in the Concurrent Training group will perform exercises for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR for 15 - 40 minutes, followed by resistance training (Quadriceps extension, leg curls, calf raise \& toe raise) using an elastic resistance band at an intensity of 60 - 80% of 1 RM, following appropriate rest intervals.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Training
Description: The patient in the Aerobic Training group will perform exercises on a treadmill for 30 - 60 minutes in 3 sessions per week for 12 weeks under the supervision of a physical therapist. Aerobic training will be performed on a treadmill at an intensity of 40 - 60 % THR, following appropriate rest intervals.
Study: NCT05540262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone
Description: Edaravone injection 30mg three times a day
Study: NCT05613504

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture treatment
Description: Acupoint selection: 4 general points + syndrome differentiation acupoints (select or replace 2-4 acupoints according to symptom 1, select 1-2 acupoints according to symptom 2 and symptom 3), and adjust acupoints according to symptoms every week.~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: Use a one-time sterile acupuncture needle (0.30×40mm, Huatuo brand), insert the needle 0.5 inch along the anatomical position, level up and relieve the qi, and keep the needle for 20 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture treatment
Description: Acupoint selection: According to the selected acupoints of the electroacupuncture group, 5-7 positions were selected at the non-meridian and non-acupoint points(points with less nerve distribution, sparseness, and rich muscles).~Frequency: 3 times a week (once every other day) for a total of 8 weeks of continuous treatment.~Operation: ① Shallow needling scheme: use a disposable sterile acupuncture needle, insert the needle 0.2 inch, without twisting, and keep the needle for 20 minutes. ②Non-invasive acupuncture plan: choose a special comfort needle with no needle tip at the top of the needle, paste a disposable sterile foam pad on the non-acupoint, and use a disposable sterile flat head The acupuncture needles were pierced into the foam pad, lightly touching but not piercing the skin, and not breathing; the needles were kept for 20 minutes.
Study: NCT04769895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MaaT013
Description: MaaT013 is made of allogeneic, full-ecosystem pooled biotherapeutic intestinal microbiota
Study: NCT06401096

Intervention type: PROCEDURE
Intervention: Preoperative respiratory exercises
Description: The Triflo Exerciser
Study: NCT04983225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Dental Pulp Stem Cells
Description: Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Dental Pulp Stem Cells
Description: Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Dental Pulp Stem Cells
Description: Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Dental Pulp Stem Cells
Description: Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Dental Pulp Stem Cells
Description: Investigational drugs: based on initial periodontal therapy (supragingival cleansing, subgingival scaling and root planning), human dental pulp stem cell injection will be given for a single local injection;

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Blank control: initial Basal periodontal therapy (supragingival cleansing, subgingival scaling and root planning) followed by a single local injection of normal saline.
Study: NCT04605393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: CBD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: THC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delta-9-THC
Description: THC
Study: NCT04764084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib 100mg or 200mg, PO, qd，d1-d21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg, PO, qd，d1-d14
Study: NCT00698074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronisation Therapy
Description: Biventricular Pacemaker Implant
Study: NCT05810506

Intervention type: OTHER
Intervention: In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
Description: In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.

Intervention type: OTHER
Intervention: In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
Description: In the study, biochemical parameters will be taken from the anthropometric measurements and files of the patients without any intervention.
Study: NCT04890977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Talking Story
Description: A culturally grounded modular intervention to increase mental health treatment-seeking among Pacific Islanders.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Talking Story
Description: A culturally grounded modular intervention to increase mental health treatment-seeking among Pacific Islanders.
Study: NCT05383092

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Physical Activity Strong
Description: Children will practice physical activities combining aerobics and muscle strengthening. They will follow a 30-minute (for prepubescent children) or 60-minute (for pubescent children) Strong adapted physical activity session 2 to 3 times a week during hospitalization periods or by videoconference at home when they are not hospitalized.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity Strong
Description: Children will practice physical activities combining aerobics and muscle strengthening. They will follow a 30-minute (for prepubescent children) or 60-minute (for pubescent children) Strong adapted physical activity session 2 to 3 times a week during hospitalization periods or by videoconference at home when they are not hospitalized.
Study: NCT04566133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: orally 2 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: orally 600 mg twice a day-1,200 mg total dose
Study: NCT04889521

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. Study is cross-sectional observational.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention. Study is cross-sectional observational.
Study: NCT06606574

Intervention type: OTHER
Group type: OTHER
Intervention: Titration protocol
Description: A standardized titration protocol for ITB will be used and the ITB dose will be increased to the next step if 1) there is persistent hypertonia identified on the dystonia screener or ASAS total spasticity, or 2) there is room for improvement on the D-FIS, and 3) there are no detrimental side effects (e.g., worsening head control). This will be continued until 1) dystonia and spasticity have been eliminated or no longer deemed as functionally impairing by the medical team, 2) side effects prevent further titration, or 3) a maximum dose of 2000 mcg/day has been reached. Once steady state is reached, this new dose becomes the maintenance dose for the rest of the trial. If there are detrimental side effects, the child will be seen weekly to confirm resolution of side effects. If side effects persist, the child will be reduced at each visit to the previous step. Once side effects are controlled, this new dose becomes the child's maintenance dose for the rest of the trial.
Study: NCT06614296

Intervention type: PROCEDURE
Intervention: Crenel Lateral Interbody Fusion
Description: The Crenel Lateral Interbody Fusion (CLIF) is a surgical technique developed by the Department of Spine Surgery at the Second Affiliated Hospital of Zhejiang University School of Medicine. Building on the traditional Lateral Lumbar Interbody Fusion technique, this series of technical improvements overcomes the shortcomings of previous surgical methods, enhancing the safety, operability, and effectiveness of the surgery while reducing complications.

Intervention type: PROCEDURE
Intervention: Crenel lateral interbody fusion plus second stage surgery
Description: The patient was first admitted to undergo CLIF surgery and was discharged after the operation. The patient will return to the hospital for a second surgery at the scheduled time.
Study: NCT06617884

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait and balance training
Description: The training includes individually adapted, targeted, video-based coordination and balance training, which should lead to an improvement in gait and balance. It includes strength, coordination and flexibility exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait and balance training
Description: The training includes individually adapted, targeted, video-based coordination and balance training, which should lead to an improvement in gait and balance. It includes strength, coordination and flexibility exercises.
Study: NCT06621225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence
Description: Medtronic GI Genius is an advanced AI-powered platform designed to assist gastroenterologists during colonoscopies. Utilizing deep learning algorithms, it analyzes real-time endoscopic images to detect and highlight polyps and other abnormalities, enhancing the detection rate and accuracy. The system provides visual cues to guide physicians in identifying potentially problematic areas that might be missed by the human eye alone. This technology aims to improve diagnostic precision, reduce missed detections, and ultimately enhance patient outcomes by facilitating earlier and more accurate interventions. GI Genius integrates seamlessly with existing endoscopy equipment, offering a valuable tool in the fight against colorectal cancer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucosal Exposure Device
Description: The Olympus Endocuff is an innovative device designed to enhance the effectiveness of colonoscopy procedures. It is a soft, flexible cuff that attaches to the end of the colonoscope and features multiple protruding \&#34;fingers\&#34; that help to improve mucosal exposure. By providing better visibility and maneuverability, the Endocuff helps gastroenterologists navigate and inspect the colon more thoroughly. It aids in the detection of polyps and other abnormalities by flattening folds and improving the overall view of the colon lining. This enhanced visualization contributes to more accurate diagnoses and can potentially reduce the miss rate of significant lesions, ultimately leading to better patient outcomes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mucosal Exposure Device
Description: The Olympus Endocuff is an innovative device designed to enhance the effectiveness of colonoscopy procedures. It is a soft, flexible cuff that attaches to the end of the colonoscope and features multiple protruding \&#34;fingers\&#34; that help to improve mucosal exposure. By providing better visibility and maneuverability, the Endocuff helps gastroenterologists navigate and inspect the colon more thoroughly. It aids in the detection of polyps and other abnormalities by flattening folds and improving the overall view of the colon lining. This enhanced visualization contributes to more accurate diagnoses and can potentially reduce the miss rate of significant lesions, ultimately leading to better patient outcomes.
Study: NCT06621524

Intervention type: DEVICE
Intervention: EucaLimus coronary stent system
Description: The EucaLimus coronary stent system is a drug-coated coronary stent system, indicated for use in patients with symptomatic ischaemic coronary heart disease due to de novo lesions or restenosed lesions of the coronary arteries.
Study: NCT06622018

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Seashell Nanoparticles and Gluma Desensitizer
Description: Evaluation the effect of Seashell Nano Particles and Gluma desensitizer on sensitivity of the teeth for Intra coronal restoration at different times

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seashell Nanoparticles and Gluma Desensitizer
Description: Evaluation the effect of Seashell Nano Particles and Gluma desensitizer on sensitivity of the teeth for Intra coronal restoration at different times

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Seashell Nanoparticles and Gluma Desensitizer
Description: Evaluation the effect of Seashell Nano Particles and Gluma desensitizer on sensitivity of the teeth for Intra coronal restoration at different times
Study: NCT06620185

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FLUENZ
Description: LAIV (Intranasal Influenza Vaccine)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza challenge virus
Description: Influenza challenge virus (H3N2 strain)
Study: NCT06618573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid/Pyridoxine
Description: Treatment group received isoniazid 300mg and pyridoxine 10mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saccharum Lactis
Description: Control group received placebo
Study: NCT06622577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cysteine
Description: Cysteine supplementation would be given according to the 2001 ROSS guidelines for the HCU. Cys amino acid supplements are available in the form of powder, each sachet containing 4gm which provides 500mg of Cys per sachet that is available in HMC medical store from where patients receive the medical formula and food at free of cost. The dosage of cysteine will be calculated according to the weight of the patient with the age specific recommendation and prescribed by the metabolic dietitian which will be approved by the metabolic physician prior to the supply of cysteine supplements to the patients. It is not known to have any serious adverse events that is life threatening. A single arm interventional study is opted as the intervention involves all the participants without withholding the treatment. Moreover, a single arm interventional study on cysteine supplementation aims to provide evidence on its efficacy contributing to the advancement of clinical practice in HCU management.
Study: NCT06618963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab Injection
Description: Omalizumab is a monoclonal antibody FDA-approved for treatment of food allergy.
Study: NCT06622863

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral hygiene instructions will be given verbally by the periodontics resident
Description: Standard oral hygiene instructions will be given verbally by the periodontics resident

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Avatar-based group will receive oral hygiene instructions from a digital avatar of their choice
Description: Avatar-based group will receive oral hygiene instructions from a digital avatar of their choice
Study: NCT06619431

Intervention type: DEVICE
Intervention: Mobile Application
Description: Rumbo is an easily shared bi-lingual application that helps Hispanic individuals with unhealthy substance use find and access treatment services and related resources. The application stands out from other eHealth tools by leveraging the collective efficacy of the Hispanic community to overcome barriers and support individuals' self-efficacy for engaging the treatment system. Rumbo's simple, user-centered design provides less-acculturated Hispanic individuals with a culturally appropriate tool to understand their needs within the complex US treatment system. Rumbo is comprised of four innovations: (1) a sharing function that facilitates its own implementation among the target population; (2) culturally responsive content and design; (3) problem identification and treatment navigation enhanced to include related resources; (4) an API that is designed for interoperability across extant technologies.
Study: NCT06617988

Intervention type: OTHER
Intervention: Not applicable- observational study
Description: Not applicable- observational study

Intervention type: OTHER
Intervention: Not applicable- observational study
Description: Not applicable- observational study

Intervention type: OTHER
Intervention: Not applicable- observational study
Description: Not applicable- observational study

Intervention type: OTHER
Intervention: Not applicable- observational study
Description: Not applicable- observational study
Study: NCT06618183

Intervention type: DIAGNOSTIC_TEST
Intervention: Fingerprint sweat drug screen
Description: Qualitative lateral-flow immunoassay analysis of fingerprint sweat specimen

Intervention type: DIAGNOSTIC_TEST
Intervention: Fingerprint sweat drug screen
Description: Qualitative lateral-flow immunoassay analysis of fingerprint sweat specimen

Intervention type: DIAGNOSTIC_TEST
Intervention: Fingerprint sweat drug screen
Description: Qualitative lateral-flow immunoassay analysis of fingerprint sweat specimen

Intervention type: DIAGNOSTIC_TEST
Intervention: Fingerprint sweat laboratory analysis
Description: Laboratory analysis of fingerprint sweat specimen by liquid chromatography/tandem mass spectrometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Fingerprint sweat laboratory analysis
Description: Laboratory analysis of fingerprint sweat specimen by liquid chromatography/tandem mass spectrometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Fingerprint sweat laboratory analysis
Description: Laboratory analysis of fingerprint sweat specimen by liquid chromatography/tandem mass spectrometry
Study: NCT06620367

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional guided bone regeneration
Description: 10 sites with medium horizontal ridge defect will be treated with bone graft (50%autogenous mixed with 50%xenograft) covered with bilayer collagen membrane stabilized by tacks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: digital guided bone regeneration
Description: 10 sites with medium horizontal ridge defect will be treated with bone graft (50%autogenous mixed with 50%xenograft) placed by digital designed guide covered with bilayer collagen membrane stabilized by tacks
Study: NCT06618885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SUM-101
Description: Three immunizations every 4 weeks for 3 months (total 3 immunizations)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SUM-101
Description: Three immunizations every 4 weeks for 3 months (total 3 immunizations)
Study: NCT06629584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Patients will receive asciminib 80 mg PO once daily continuously for 28-day cycles for 2 years.